Gustavo Arango-Argoty

New Capabilities

AstraZeneca researcher

For decades, cancer drug trials have failed at a rate exceeding 95%—burning through $50-60 billion annually on treatments tested in patients who were never likely to respond. On April 17, 2025, researchers from AstraZeneca and Tempus AI published results in Cancer Cell showing that the Predictive Biomarker Modeling Framework (PBMF)—a machine learning system using contrastive learning—can identify, from existing clinical data, which cancer patients will survive longer on immunotherapy versus chemotherapy. Applied retrospectively to completed phase 3 trials, the system improved survival outcomes by 15% compared to traditional patient selection.

Updated Feb 11